Barinthus Biotherapeutics (BRNS) Projected to Announce Quarterly Earnings on Friday

Barinthus Biotherapeutics (NASDAQ:BRNS) will likely be issuing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $0.22 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. On average, analysts expect Barinthus Biotherapeutics to post ($0.93) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock opened at $0.74 on Thursday. The firm’s 50-day moving average price is $0.74 and its 200 day moving average price is $0.66. The firm has a market capitalization of $30.23 million, a PE ratio of -0.72 and a beta of -0.37. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BRNS. Weiss Ratings cut shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Zacks Research raised shares of Barinthus Biotherapeutics to a “hold” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Barinthus Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing T-cell immunotherapies designed to treat autoimmune diseases, chronic infections and cancer. The company’s approach is intended to direct or regulate immune responses with greater specificity, with the goal of restoring immune tolerance or strengthening disease-fighting T-cell activity.

Barinthus’ product pipeline includes VTP-1000, an investigational antigen-specific therapy being developed for celiac disease, and VTP-300, a therapeutic vaccine candidate aimed at chronic hepatitis B infection.